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Abstract
Background: The diagnosis of mitochondrial disorders is challenging because of the 
clinical variability and genetic heterogeneity of these conditions. Next‐Generation 
Sequencing (NGS) technology offers a robust high‐throughput platform for nuclear 
and mitochondrial DNA (mtDNA) analyses.
Method: We developed a custom Agilent SureSelect Mitochondrial and Nuclear 
Disease Panel (Mito‐aND‐Panel) capture kit that allows parallel enrichment for sub-
sequent NGS‐based sequence analysis of nuclear mitochondrial disease‐related 
genes and the complete mtDNA genome. Sequencing of enriched mtDNA simulta-
neously with nuclear genes was compared with the separated sequencing of the mi-
tochondrial genome and whole exome sequencing (WES).
Results: The Mito‐aND‐Panel permits accurate detection of low‐level mtDNA het-
eroplasmy due to a very high sequencing depth compared to standard diagnostic 
procedures using Sanger sequencing/SNaPshot and WES which is crucial to identify 
maternally inherited mitochondrial disorders.
Conclusion: We established a NGS‐based method with combined sequencing of the 
complete mtDNA and nuclear genes which enables a more sensitive heteroplasmy 
detection of mtDNA mutations compared to traditional methods. Because the method 
promotes the analysis of mtDNA variants in large cohorts, it is cost‐effective and 
simple to setup, we anticipate this is a highly relevant method for sequence‐based 
genetic diagnosis in clinical diagnostic applications.
K E Y W O R D S
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1 |  INTRODUCTION
Mitochondrial disease is highly heterogeneous in cause and fea-
tures; therefore, traditional single‐gene testing strategies have 
had limited diagnostic success (McCormick, Place, & Falk, 
2013). Due to clinical variability and large number of both nu-
clear and mitochondrial genes in which mutations can occur, 
parallel analysis of mtDNA and nuclear DNA within a routine 
diagnostic test is of great advantage in diagnosing mitochon-
drial diseases at the molecular level. Given the heteroplasmy 
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of mitochondrial genomes, as well as the sequences of mito-
chondrial origin in the nuclear genome (NUMTs, nuclear mi-
tochondrial DNAs), the dual analysis of genomic and mtDNA 
variants in a single NGS approach is challenging. The fact 
that subject DNA samples typically contain >100× copies of 
mtDNA molecules compared to nuclear DNA molecules is 
known to introduce bias in the dual sequence enrichment with 
the current targeted‐capture protocols (Calvo et al., 2012). In 
addition, deeper sequencing coverage of mtDNA compared to 
nuclear DNA is necessary to reliably detect low‐level hetero-
plasmic variants (Falk et al., 2012). While a mean coverage 
depth of 120× is usually enough for detection of nuclear DNA 
variants, a minimal depth of >1,000× reads may be acceptable 
for the detection of low‐heteroplasmic variants (Jennings et al., 
2017; Matthijs et al., 2016), meaning that much more sequenc-
ing reads have to be generated for mtDNA compared to nuclear 
DNA. Although recent studies have demonstrated the efficacy 
of NGS technologies for the genetic diagnosis of inherited mi-
tochondrial diseases (Calvo et al., 2012; Falk et al., 2012, 2015 ; 
Guo, Li, Li, Shyr, & Samuels, 2013; Legati et al., 2016; Picardi 
& Pesole, 2012; Vasta, Merritt, Saneto, & Hahn, 2012), these 
methods do not overcome the limitations and cause ineffective-
ness in terms of variant detection accuracy, turnaround time, 
and costs for separate mtDNA and nuclear DNA analysis. Here, 
we developed a NGS‐based method with combined sequencing 
of the complete mtDNA and nuclear genes causing mitochon-
drial diseases and compared this method with the traditional 
Sanger sequencing and whole exome sequencing (WES).
2 |  MATERIALS AND METHODS
2.1 | Patients and controls
DNA samples were extracted from peripheral blood (2–4 ml 
EDTA) of controls and of 17 patients with confirmed patho-
genic mtDNA variants and controls. Informed consent was 
obtained from all participants and approved by local institu-
tions (2018–027).
2.2 | Selection of nuclear genes
The Nuclear Disease Panel (ND‐Panel) targets the coding 
sequences of 1,564 nuclear genes with a known disease‐as-
sociated phenotype in humans. These 1,564 nuclear genes are 
the combined aggregate of smaller phenotype‐related gene 
panels (gene sets of 2 to >400 genes) designed to address the 
most common neurological, neuromuscular, syndromic, and 
neurodevelopmental phenotypes in a clinical diagnostic set-
ting. Phenotypes that may suggest underlying mitochondrial 
etiology include epilepsy, encephalopathy, Leigh syndrome, 
myopathy, hepatopathy, external ophthalmoplegia, optic atro-
phy, ataxia, dystonia, and stroke‐like episodes. In summary, 
308 genes of the entire panel are contained in MitoCarta 
v2.0, an inventory of 1,158 human and mouse genes encod-
ing proteins with strong support of mitochondrial localization 
(Calvo, Clauser, & Mootha, 2016) (Supporting information 
Table S1). The included MitoCarta v.2.0 genes are known 
to be associated with a mitochondrial disease phenotype in 
humans—thus confirming or strongly supporting a mitochon-
drial disorder in case of a pathogenic variant.
2.3 | Sample preparation
For panel enrichment, approximately 1.5 µg genomic DNA 
of patients was required. Targeted enrichment was performed 
with two SureSelectXT Custom Kits (Agilent Biosciences): 
The mtDNA Panel (Mito‐Panel) which targets the complete 
sequence of the mitochondrial DNA and the Nuclear Disease 
Panel (ND‐Panel) which targets the coding sequences of 
1,564 nuclear genes reported in human diseases, including 
308 genes extracted from MitoCarta v2.0. Biotinylated RNA 
oligonucleotides (baits), targeting the entire mtDNA region 
and the coding exons of 1,564 nuclear genes, were designed 
(SureSelect 2× tiling across the target hg19/GRCh37 and the 
rCRS/NC_012920.1 mitochondrial genome). Both bait de-
signs were ordered separately (Agilent Biosciences).
Given the 1–2 log natural excess of mtDNA genomes to 
the nuclear genome, blending of mtDNA capture baits will 
be necessary to ensure optimal coverage output of both ge-
nomes. First, performance of Mito‐Panel was tested in three 
negative control DNA samples (patients with no known 
pathogenic variant in the mtDNA sequence) at a ratio of 1:10, 
1:20, 1:50, and 1:100 bait dilution. Sample preparation and 
hybridization was done in triplicates. Second, performance 
of nuclear DNA and mtDNA parallel sequence capture was 
tested at various mito:ND bait molar ratios.
The validation cohort comprises 72 control samples in-
cluding both mutation negative and positive distinct patients 
and two control DNAs of the Coriell repositories (NA12889, 
RM8398). The total of 72 samples was tested subdivided 
into three different sample preparation batches of three dif-
ferent molar ratios of mito:ND baits, namely batch A—di-
lution 1:50, batch B—dilution 1:100, and batch C—dilution 
1:500 (Figure 1). The validation cohort comprised 68 nega-
tive control samples from patients and two control DNAs of 
the Coriell repositories (NA12889, RM8398) both with no 
pathogenic variant in the mtDNA sequence, which were pre-
pared in duplicate, in order to confirm the repeatability of the 
method. Each sample batch was sequenced in independent 
sequencing runs (Figure 1).
Additional 17 positive control samples (human blood 
DNAs of patients with a pathogenic variant in the mtDNA 
sequence) were analyzed with the 1:50 mito:ND bait dilution 
(Table 1A,B), and the results were compared to the results from 
conventional Sanger sequencing. Additionally, 11 of these pos-
itive control DNA samples were compared to the results of 
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whole exome sequencing (WES). WES and mtDNA enrich-
ment was performed with the SureSelect Human All Exon v6 
Kit (Agilent) following the manufacturer’s instructions. All 
sample capture libraries were prepared as described in the 
SureSelectXT Target Enrichment System for Illumina Paired‐
End Multiplexed Sequencing Library enrichment protocol.
2.4 | Sanger sequencing and SNaPshot
Sanger sequencing and single‐nucleotide allele‐specific 
primer extension (SNaPshot) analysis were used to deter-
mine the level of heteroplasmy in controls with pathogenic 
mtDNA variants (Cassandrini et al., 2006).
2.5 | High‐throughput sequencing
Sequencing sample pools of mtDNA‐only (12 patient librar-
ies per sequencing run) was performed on an Illumina MiSeq 
system Nano Flowcell (Illumina, San Diego, CA) as 150 bp 
paired‐end runs using v2.0 SBS chemistry. Sequencing of the 
Mito‐aND‐Panel and WES was carried out on an Illumina 
NextSeq 500 system (Illumina, San Diego, CA) as 150 bp 
paired‐end runs using v2.0 SBS chemistry.
2.6 | Bioinformatics pipeline
2.6.1 | Detection of SNVs
The human reference genome hg19 was adapted by exchang-
ing the outdated human mitochondrial reference sequence 
NC_001807.4 with the rCRS/NC_012920.1 sequence. 
Sequencing reads were aligned to this modified reference 
sequence using BWA (v0.7. 13‐r1126) with standard param-
eters. Duplicate reads and reads that did not map in proper 
pairs were removed. Statistics on coverage and sequencing 
depth on the clinical targeted regions (i.e., RefSeq coding 
exons and ±5 intronic region and complete mtDNA sequence 
rCRS/NC_012920.1) were calculated with a custom script. 
SNV and INDEL calling on the nuclear genes was conducted 
using SAMtools (v1.3.1) with subsequent coverage and qual-
ity‐dependent filter steps. Variant annotation was performed 
with snpEff (v4.2) and Alamut‐Batch (v1.4.4). Only variants 
F I G U R E  1  Evaluation of the capture efficiency of mtDNA when Nuclear Disease Panel (ND‐Panel) and Mito‐Panel are blended (=Mito‐
aND‐Panel) at different concentrations. The validation cohort comprises 72 control samples including both mutation negative and positive distinct 
patients and two control DNAs of the Coriell repositories (NA12889, RM8398). The total of 72 samples was tested subdivided into three different 
sample preparation batches of three different molar ratios of mito:ND baits (batch A—dilution [1:50], batch B—dilution [1:100], and batch C—
dilution [1:500]). Each sample batch was sequenced in independent sequencing runs. The height of the columns indicates the percentage of mtDNA 
covered by a minimum number of reads. Black‐colored column: minimum coverage of 100 reads, 100× coverage; gray‐colored column: minimum 
coverage of 1,000 reads, 1,000× coverage; white‐colored column: minimum coverage of 2,000 reads, 2,000× coverage. All data are expressed as 
arithmetic mean ± standard deviation of the samples
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(SNVs/small INDELs) in the coding and flanking intronic 
regions (±5 bp) were evaluated. The BAM files containing 
the mitochondrial sequencing data were analyzed separately 
with the mtDNA‐Server (v1.0.6) which detects both homo-
plasmic and heteroplasmic variants down to 1%, as well as 
possible contaminations based on haplogroup inconsisten-
cies (Weissensteiner et al., 2016). Further, it tags positions in 
low complexity regions (LCR) and every variant is annotated 
with the number of known polymorphic nuclear mitochon-
drial insertions (NUMTs) and their location in the nuclear 
genome (Dayama, Emery, Kidd, & Mills, 2014).
2.6.2 | Interpretation of mitochondrial DNA 
Copies (NUMTs) in sequenced nuclear genomes
Variants located at known polymorphic nuclear mitochon-
drial insertions (NUMTs) were tagged by the mtDNA‐Server 
(Weissensteiner et al., 2016) in all patients. All these vari-
ants were carefully evaluated regarding their molecular effect 
and presence in the MITOMAP databases to assess possible 
pathogenicity or probable NUMTs of so far unknown NUMT 
regions.
2.6.3 | Sensitivity and specificity
Sensitivity and specificity of detecting nuclear variants in 
HapMap individuals (NA12889, NA12890, RM8398) was 
estimated using independent genotype training data obtained 
from the 1,000 Genomes and National Institute of Standards 
and Technology (NIST). Genotype concordance was as-
sessed at 5,623 targeted sites.
Sensitivity and specificity of SNV detection in mtDNA 
via the mtDNA‐Server is being estimated based on the 
analysis of the validation cohort by comparing results from 
Sanger sequencing, SNaPshot, and NGS. Sanger sequencing 
is estimated to detect around 10% to 20% mutated DNA in a 
background of normal DNA (Tsiatis et al., 2010). The limit 
to detect heteroplasmic mtDNA variants may be as low as 
6% (Irwin et al., 2009). The level of heteroplasmy detected 
by SNaPshot analysis, which is used for targeted verification 
or exclusion of individual variants (Cassandrini et al., 2006), 
is as low as 5% (Naue, Sanger, Schmidt, Klein, & Lutz‐
Bonengel, 2011).
2.6.4 | Cost efficacy
The method combines testing for mutations of the mtDNA, 
and testing for mutations of frequent disease‐causing genes 
in the nuclear genome. Costs of the custom‐made targeted‐
enrichment panel (SureSelect Tier 5 Panel, Agilent, Santa 
Clara, CA, USA) addressing the 1,564 nuclear‐encoded 
genes are lower compared to an entire whole exome or whole 
genome enrichment. Although the target enrichment does not 
cover all theoretically possible disease‐causing mutations of 
the nuclear genome, it enables the analysis of a large num-
ber of disease‐causing genes with the quality required for 
diagnostic analysis (Matthijs et al., 2016) using a NextSeq 
(Illumina, San Diego, CA) sequencing platform. The addi-
tional mtDNA baits (SureSelect Tier 1 Panel, Agilent, Santa 
Clara, CA, USA) increase the costs of enrichment to only 
about 1%. Furthermore, the combination of both methods in 
one technical approach leads to considerable savings in per-
sonnel costs and turnaround time.
3 |  RESULTS
3.1 | Experimental evaluation of dual 
enrichment of mitochondrial and nuclear DNA
First, we experimentally evaluated the capture efficiency of 
the Mito‐Panel with the SureSelectXT method. Enrichment 
of three human blood DNA samples, each by one of four dif-
ferent dilutions of mito baits (1:10, 1:20, 1:50, and 1:100), 
resulted in high sequencing depth across the entire mtDNA 
genome regardless the oligo‐bait dilution factor. All data are 
expressed as standard deviation (SD). Average raw reads per 
sample were 1.79 × 104 (SD: 7.7%). Briefly, mean sequenc-
ing depth for mtDNA of three different DNA samples in trip-
licates was 1,435 (SD: 12%) for 1:10, 1,421 (SD: 7.2%) for 
1:20, 1,277 (SD: 0.8%) for 1:50, and 1,299 (SD: 8.1%) for 
1:100 dilution. Mean capture repeatability between dilutions 
was >95% (SD: 2.8%).
Second, we evaluated the capture efficiency of nuclear and 
mtDNA genes when ND‐Panel and Mito‐Panel are blended 
(=Mito‐aND‐Panel) at different concentrations (Figure 1). 
Given the 1–2 log natural excess of mtDNA genomes to the nu-
clear genome, we sought to assess the optimal output of nuclear 
versus mtDNA genome by manually blending capture baits at 
different molar ratios. The aim of this experiment was to re-
tain the ability to detect low‐level mtDNA variant heteroplasmy 
by high sequencing depth, but also maintain the diagnostic ac-
curacy of variant detection in the nuclear genes by achieving 
sufficient sequencing depth of the ND‐Panel. Subsequently, 
we tested a total of 72 samples for this capture method subdi-
vided into three different sample preparation batches of three 
different molar ratios of mito:ND baits (batch A—1:50, batch 
B—1:100, and batch C—1:500) as described above (Figure 
1). Average raw reads per sample were 44 × 106 (SD 17.9%). 
A mean sequencing depth of 7,373 (SD 18.1%)—batch A, 
4,882 (SD 33.4%)—batch B, and 769 (SD 21.7%)—batch C 
was achieved on the complete mtDNA genome. The mean se-
quencing depth of the targeted regions of the ND‐Panel genes 
was 591 (SD 17.2%)—batch A, 666 (SD 12.5%)—batch B, and 
491 (SD 7.8%)—batch C. All dilutions (batch A—1:50, batch 
B—1:100, batch C—1:500) showed a mean coverage of >99% 
of at least 30× for the coding regions of the ND‐Panel genes.
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Specifically, 99.6% (SD 0.1%) of the clinical target of the 
308 captured nuclear mitochondrial genes that are usually se-
quenced in a diagnostic setting reached a sequencing depth 
of more than 30×. Furthermore, an optimal mtDNA genome 
coverage was achieved for all samples, detecting 100% of 
mtDNA genome bases covered at 100×, 99% of mtDNA ge-
nome bases covered at 1,000× coverage, and 98% of mtDNA 
genome bases covered at 2,000× as mean values of the 24 
batch A samples with 1:50 dilution. Higher dilution molar 
ratios (1:100 and 1:500) showed a reasonable fall‐off in the 
mtDNA genome coverage of at least 1,000× to 98% and 18%, 
respectively. Therefore, a molar ratio of mito:ND baits of 
1:50 was used for all Mito‐aND‐Panel analyses.
3.2 | Variant detection in nuclear genes and 
mtDNA genome heteroplasmy by Mito‐aND‐
Panel
The accuracy and reproducibility of variant detection in the 
ND‐Panel genes within the Mito‐aND‐Panel were assessed 
using three reference DNAs (Coriell Institute for Medical 
Research: NA12889, NA12890, RM8398). Sensitivity and 
positive predictive value (PPV) for the detection of nuclear 
single‐nucleotide variants (SNVs) were 99.91% and 99.79% 
for SNPs and 94% and 97% for InDels respectively, based on 
5,623 sites with at least 20× read‐depth, which according to 
guidelines is sufficient for NGS‐based diagnostic purposes 
(Matthijs et al., 2016).
The performance of the mitochondrial variant calling 
of the mtDNA‐Server has been assessed by the authors 
(Weissensteiner et al., 2016). For that, an analysis with Ion 
Torrent data with an average coverage of 5,000× showed 
a sensitivity of 77.78% for heteroplasmy levels of 2% and 
81.48% for heteroplasmy levels of 10%. Both specific-
ity and PPV are estimated to be 100% in the tested cases 
(Weissensteiner et al., 2016). We expect the Mito‐aND‐Panel 
analysis to outperform these estimations due to a higher aver-
age coverage and the lower error rate of Illumina sequencing 
systems compared to Ion Torrent.
3.3 | Mito‐aND‐Panel enables a more 
sensitive heteroplasmy detection compared 
to Sanger sequencing and whole exome 
sequencing in leukocytes
To assess the diagnostic yield of the combined nuclear and 
mitochondrial DNA capturing method, we compared its ef-
ficiency to identify mtDNA variants to standard diagnostic 
procedures using WES and Sanger sequencing/SNaPshot.
A total of 17 positive control samples from patients with 
known pathogenic variants MT‐ATP6 (m.8993T > G), MT‐TK 
(m.8344A > G), or MT‐TL1 (m.3243A > G) in mtDNA were 
enriched with 1:50 bait dilution and subsequently sequenced by 
NGS. The level of variant heteroplasmy in this cohort had been 
previously determined by Sanger sequencing and SNaPshot anal-
ysis. In all 17 patients, NGS technology allowed the detection of 
the underlying homoplasmic or heteroplasmic mtDNA variants.
A Bland–Altman plot was created for analyzing the agree-
ment between Sanger sequencing and NGS heteroplasmy 
measurements (Figure 2). The mean value of the difference 
(NGS/Sanger = 0.94) between the two measurements was 
different from 0, indicating that there was a systemic differ-
ence between the two methods. However, 16 of 17 values lay 
within the 95% limits of agreement (Figure 2).
F I G U R E  2  Bland–Altman plot for depicting the agreement between NGS (next‐generation sequencing) and Sanger sequencing/SNaPshot 
heteroplasmy measurements. On the x‐axis, the average of NGS and Sanger sequencing heteroplasmy is plotted. On the y‐axis, the difference 
between next‐generation and Sanger sequencing/SNaPshot heteroplasmy is plotted. The mean difference is indicated as green line, the 95% limits of 
agreement (average difference ± 1.96 standard deviation of the difference) are indicated as red dotted lines. Two of the 17 samples showed exactly 
the same difference between Sanger sequencing/SNaPshot and NGS heteroplasmy measurements, thus only 15 dots of 17 calculated samples are 
shown in the figure
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Importantly, Mito‐aND‐Panel allowed a more precise 
detection of heteroplasmic mtDNA variants (up to 3.5%) 
compared to Sanger sequencing/SNaPshot (Table 1A,B). 
Interestingly, in one patient, the mtDNA variant MT‐TL1 
(m.3243A > G) was not detected in blood‐extracted DNA by 
Sanger sequencing/SNaPshot, but had been shown to be pres-
ent in muscle‐extracted DNA in 70% heteroplasmy. Analysis 
with Mito‐aND‐Panel was able to detect 3.5% heteroplasmy 
of the pathogenic mtDNA variant MT‐TL1 (m.3243A > G) 
in the blood DNA sample of this patient, indicating a more 
sensitive variant detection by Mito‐aND‐Panel by a high 
resolution for low‐heteroplasmy rate due to a high mtDNA 
coverage of >7,000× compared to the Sanger sequencing/
SNaPshot method.
To further assess the efficiency to identify mtDNA vari-
ants by Mito‐aND‐Panel compared to WES, 11 blood DNA‐
positive control samples were in parallel tested by WES 
(Table 1B). WES enrichment and sequencing generated a 
total of nine Megabases of sequence resulting in a mean nu-
clear exome sequencing depth of 190× with more than 97% 
of exome targets being covered with at least 30×. Coverage 
analysis of the mtDNA showed a mean sequencing depth 
of 39.2 (SD 48.0%) and 91.78% of mtDNA genome bases 
covered at 10×, 60.71% bases covered at 30× coverage, and 
2.95% of bases covered at 100×. Heteroplasmy was detect-
able in seven of 11 patients as WES was not able to detect 
variants with heteroplasmy levels below 20% (Table 1B).
3.4 | Detection of NUMTs with the mtDNA‐
Server
mtDNA is known to have been inserted into nuclear DNA to 
form NUMTs over the course of evolution (Mishmar, Ruiz‐
Pesini, Brandon, & Wallace, 2004). Since NUMTs share 
strong sequence similarities with mtDNA genes, off‐target 
NUMTs capture and the subsequent alignment to the mtDNA 
genome usually introduces bias in the detection of heteroplas-
mic mtDNA variants. The mtDNA‐Server annotates variants 
with known NUMTs according to Dayama et al. (Dayama et 
al., 2014). We detected both low‐level variants correspond-
ing to known NUMTs and low‐level variants not assigned to 
known NUMTs regions.
4 |  DISCUSSION
Here, we established the Mito‐aND‐Panel for parallel se-
quencing of the entire mtDNA and 1,564 nuclear DNA 
genes, including 308 nuclear mitochondrial disease‐related 
genes (MitoCarta v2.0) that achieves variant detection at high 
resolution for low‐heteroplasmic mtDNA mutations (down 
to 3.5%) at a mean coverage of >7,000×. In addition, analy-
sis of nuclear genes reaches the required accuracy of 99.9% 
sensitivity in 99% of the analyzed region, as recommended 
by current guidelines for NGS diagnostics (Matthijs et al., 
2016).
Current methods for the genetic diagnosis of inherited 
mitochondrial diseases had limitations in terms of variant 
detection accuracy, turnaround time, and costs for separate 
mtDNA and nuclear DNA analysis. The Mito‐aND‐Panel we 
present here is a sensitive and accurate method, which over-
comes these limitations.
Accurate and sensitive methods are necessary to en-
able the detection and quantification of low‐heteroplasmic 
variants of mtDNA. The quantification of mtDNA hetero-
plasmy is both challenging and of particular clinical rel-
evance because mtDNA mutations exert their phenotypic 
effect above a certain mutation load threshold, which may 
vary depending on the type of change and tissue (Chinnery 
& Hudson, 2013; Gasparre et al., 2011; Rossignol et al., 
2003).
A variety of techniques have been used for heteroplasmy 
detection, including Sanger sequencing (Irwin et al., 2009), 
SNaPshot (Cassandrini et al., 2006), high‐performance liquid 
chromatography (HPLC) (Meierhofer, Mayr, Ebner, Sperl, & 
Kofler, 2005), pyrosequencing (Mikkelsen, Frank‐Hansen, 
Hansen, & Morling, 2014), high‐resolution melt (HRM) 
profiling (Dobrowolski et al., 2009), a temporal temperature 
gradient gel electrophoresis (TTGE) strategy (Wong, Chen, 
& Tan, 2004), the Invader Assay (Mashima et al., 2004), am-
plification refractory mutation system (Bai & Wong, 2004), 
and surveyor nuclease (Bannwarth, Procaccio, & Paquis‐
Flucklinger, 2005).
Each of the mentioned strategies has its own disadvan-
tages (Sobenin et al., 2014). For some methods, the can-
didate heteroplasmic position needs to be defined first, 
the method may not allow determination of the actual 
heteroplasmic position, or the method is too labor inten-
sive to be applicable to large numbers of samples. Most 
of the techniques were unable to detect the mutation when 
present below 20% and the level of heteroplasmy cannot 
be quantified accurately. HRM, HPLC, and endonuclease 
method may be excellent for qualitative detection of hetero-
plasmy itself, but the methods have insufficient resolution 
for the quantitative measurement of mtDNA heteroplasmy 
level. The limit to detect heteroplasmic mtDNA variants 
in Sanger sequencing may be as low as 6% (Irwin et al., 
2009), but in general a detection limit of about 10% to 20% 
to detect low‐level mutant alleles (Tsiatis et al., 2010) is 
estimated. SNaPshot sequencing has insufficient resolution 
in measuring the content of the mutant allele of <5% (Naue 
et al., 2011) and can only be applied as targeted testing to 
confirm or to exclude a specific variant. Pyrosequencing 
provides high accuracy for the quantitative measurements 
of heteroplasmy levels but the method is extremely expen-
sive and may thus limit the possibility of routine analysis 
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of a large number of samples. Moreover, the limit of de-
tection will depend on many factors including sequence 
quality, personnel experience, sequence context, and use of 
bidirectional data. Importantly, the efficiency of detection 
can vary for each method from laboratory to laboratory, as 
a result of different instruments, chemistries, or standards 
for calling heteroplasmy (Hancock, Tully, & Levin, 2005; 
Prieto et al., 2008).
Next‐Generation Sequencing technologies enable studies 
of heteroplasmy across the entire mtDNA genome at much 
higher resolution, because many independent reads are gen-
erated for each position thus overcoming limitations of cur-
rent methods. The currently most reliable and sensitive NGS 
method for detecting almost all clinically relevant mitochon-
drial DNA defects including both point mutations and large‐
scale deletions of mitochondrial DNA is long‐range PCR 
followed by massive parallel sequencing (Cui et al., 2013). 
However, this requires several separate reaction steps so that 
this procedure cannot be directly integrated into the work-
flow of the standard NGS sequencing of nuclear genes.
The single Mito‐aND enrichment approach we present 
here was able to generate over 100 Megabases of sequence 
of mtDNA and two Gigabases of genomic DNA in a single 
targeted‐capture assay. This translates into >10‐times more 
fold coverage for mtDNA in relation to nuclear DNA, which 
is sufficient for accurate heteroplasmic detection and, in ad-
dition, allows dual analysis of mtDNA and nuclear genes. 
High‐coverage NGS sequencing might even detect variants 
in leukocyte‐extracted DNA which are below the limit of 
detection in Sanger sequencing, and otherwise have to be 
identified in different tissues with higher heteroplasmy levels 
(Whittaker et al., 2009). This is exemplified by the results of 
one patient who showed 70% heteroplasmy for the MELAS 
variant m.3243A > G (MT‐TL1) in muscle biopsy. In leuko-
cyte‐extracted DNA, the variant was not identified by Sanger 
sequencing, but Mito‐aND‐Panel was able to detect 3.5% 
heteroplasmy. Thus, the Mito‐aND‐Panel provides a sim-
ple, high‐throughput platform for mitochondrial genome 
sequencing for accurate mtDNA heteroplasmy detection. 
However, the method may still miss some low‐level hetero-
plasmic mtDNA SNVs in blood specimens but high‐level in 
other type of tissues such as muscle or urine (Whittaker et 
al., 2009).
Beside point mutations, single large‐scale deletions 
in mtDNA are a common cause of mitochondrial disease 
(DiMauro & Hirano, 1993; Picard, Vincent, & Turnbull, 
2016). Single large‐scale mtDNA deletions are especially 
associated with three very well characterized phenotypes, 
Kearns–Sayre syndrome (KSS), Pearson syndrome, chronic 
progressive external ophthalmoplegia (CPEO), and rarely 
Leigh syndrome. Approximately 90% of individuals with 
KSS have a large‐scale mtDNA deletion that is usually pres-
ent in all tissues but mutated mtDNA is often undetectable 
in blood leukocytes, necessitating muscle biopsy. In CPEO, 
mtDNA deletions are confined to skeletal muscle. In Pearson 
syndrome, mtDNA deletions are usually more abundant in 
blood than in other tissues. Currently, a major limitation of 
the Mito‐aND‐Panel is the missing CNV detection. Even if 
an adapted bioinformatics pipeline might enable CNV de-
tection, low‐levels of heteroplasmy and mtDNA deletions 
confined to muscle will remain a limiting factor. Therefore, 
screening for single large‐scale mtDNA deletions—using a 
suitable method and tissue—is necessary to complete the di-
agnosis of mitochondrial disease, especially in the presence 
of a characteristic clinical phenotype suggesting mtDNA de-
letion syndrome.
Due to the high sensitivity of NGS sequencing, the detec-
tion rate of low‐frequency variants is increasing and inter-
pretation of the data is challenging. Interpretation of mtDNA 
variants is further complicated by the presence of nuclear 
DNA regions homologous to mtDNA. These regions, called 
NUMTs, are the result of an extensive mtDNA pseudogeni-
zation in the nuclear genome during evolution. They can be 
found as blocks of several kilobases, highly homologous to 
the genuine mtDNA sequence, and spread as multiple copies 
throughout the genome. Some NUMTs seem to be univer-
sal, whereas others may be specific to some subpopulations 
(Dayama et al., 2014). NGS following targeted enrichment of 
mtDNA, alone or in combination with targeted enrichment of 
nuclear DNA, is hampered by the off‐target capture of NUMT 
sequences. Only amplification of the complete mitochondrial 
genome using long‐range PCR followed by NGS sequencing 
provides the greatest level of specific mtDNA enrichment, 
approaching 100% of the mtDNA avoiding false variant calls 
in NUMTs, and enabling a successful detection of hetero-
plasmic variants (Douglas et al., 2014). However, sequencing 
artefacts arising from the high‐fidelity polymerase diminish 
variant detection accuracy (Gould et al., 2015) and further 
analysis of nuclear genes is only possible by an additional 
separate analysis. Prior separation of the mitochondrial ge-
nome from the nuclear genome has been shown to overcome 
the problems of PCR amplification; however, this method re-
mains nontrivial and is difficult to apply in routine diagnos-
tics (Gould et al., 2015).
We show that our pipeline approach in combination with 
the mtDNA‐Server workflow, (Weissensteiner et al., 2016), 
correctly annotated low‐level variants corresponding to 
known NUMTs. Thus, interpretation of very low‐frequency 
mtDNA variants is further complicated by NUMTs and the 
clinical relevance should always be evaluated in context with 
the ACMG classification, the clinical phenotype of the pa-
tient and possibly the detection of the variant in different tis-
sue depending on the tissue‐specific threshold.
Since mitochondrial diseases are very heterogeneous in 
terms of clinical presentation and the number of possible 
underlying defects in nuclear‐encoded genes, a common 
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strategy in diagnostics and research is WES. Even without 
targeted mtDNA sequencing, mtDNA sequences can be ex-
tracted from exome sequencing data, greatly increasing the 
range of mitochondrial genetics data available for research 
purposes. Various research groups have used this approach to 
increase their diagnostic yield. Dinwiddie et al. demonstrated 
the utility of using a standard exome kit for examining the 
mtDNA and discovery of both homoplasmic and heteroplas-
mic variants (Dinwiddie et al., 2013). The study presented 
four cases where exome sequencing yielded a molecular di-
agnosis after none was identified by conventional methods. 
One patient was found to have Leigh syndrome due to a mu-
tation in MT‐ATP6, two affected siblings were discovered to 
be compound heterozygous for mutations in the NDUFV1 
gene, which causes mitochondrial complex I deficiency, and 
one patient was found to have coenzyme Q10 deficiency due 
to compound heterozygous mutations in COQ2. Exome en-
richment was conducted with Illumina TruSeq Exome v1 kit 
(62.2 Megabases). Sequencing was performed on an Illumina 
HiSeq 2000 using v3 reagents and 1× 101 basepair sequenc-
ing reads. Using this method, they obtained greater than 50× 
coverage of uniquely aligning reads with six Gigabase or 
more sequencing, which allows for analysis of both the nu-
clear and mtDNA genomes.
Moreover, Diroma et al. showed that analysis of mito-
chondrial DNA from off‐target WES enrichment studies is 
by far not sufficient for a robust detection of low mtDNA 
heteroplasmies as coverage and sequencing depth are highly 
variable (between 47% and 97% ≥ 1× coverage and mean 
mtDNA per base depth between 25 and 410) (Diroma et al., 
2014). Our results confirm this observation. We were not able 
to detect mtDNA pathogenic variants in 4 out of 11 patients 
with known mtDNA pathogenic heteroplasmic variants from 
WES data. Mean sequencing depth was between 7.4× and 
79.7×, and therefore quite low compared to others (Diroma 
et al., 2014). This may be due to the used WES NGS tech-
nology and coverage might have been higher if using a dif-
ferent sequencing platform. Indeed, several studies reported 
that there is a difference in the coverage of the off‐target 
enriched mtDNA using exome kits from different manufac-
tures (Picardi & Pesole, 2012). However, the exome kit and 
sequencing platform used in our study are widely used and 
are often applied in clinical diagnostics.
Falk and co‐workers optimized the whole exome anal-
ysis by blending additional baits targeting the mtDNA se-
quence and the complete MitoCarta nuclear gene set into a 
standard 50 Mb whole exome kit thus optimizing mtDNA 
coverage (Falk et al., 2012). This approach which showed 
99.8% of the mtDNA genome at 1,000× coverage depth 
enabled heteroplasmy detection between 7.8% and 8.3%. 
However, 97.5% of the targeted nuclear genomic regions 
reached a maximum sequencing depth of 10×, which is 
not sufficient for diagnostic purposes according to current 
guidelines (Matthijs et al., 2016). Heterozygous variants 
will be missed in 5% of the cases if 96% of the target is 
covered at 20×.
Our data show that limiting the analysis to less nuclear‐
encoded genes significantly improves the detection rate for 
mtDNA variants, compared to WES, in addition to a high‐
coverage sequencing of nuclear genes after targeted enrich-
ment. Thus, it was possible to meet the diagnostic quality 
requirements according to international guidelines. The 
mean coverage of 7,373 for mtDNA sequences corresponded 
well to the recommended mean coverage of >2,000 for the 
detection of somatic mutations (Jennings et al., 2017). In all 
patients, nuclear gene panel analyses fulfilled type B testing 
according to the EJHG guidelines (Matthijs et al., 2016).
In summary, we demonstrated the custom Agilent 
SureSelect Mito‐aND‐Panel as an NGS‐based method for the 
parallel analysis of targeted nuclear genes and the complete 
mtDNA, which allows accurate detection of low‐level mtDNA 
heteroplasmy due to a very high sequencing depth, compared 
to traditional methods in blood samples. Since costs of the 
custom‐made targeted‐enrichment Mito‐aND‐Panel are lower 
compared to an entire whole exome or genome sequencing 
and the method is simple to setup, we anticipate this is a 
highly relevant cost‐effective method for sequence‐based ge-
netic diagnosis in clinical diagnostic applications. Compared 
to WES, the limitation of using this panel in suspected nu-
clear mitochondrial disorders is that pathogenic variants in 
novel nuclear mitochondrial or nonmitochondrial disease 
genes are not identified. Thus, for clinical molecular diagno-
sis the gene list should be updated and the panel should be 
redesigned regularly. A further technical improvement of tar-
geted enrichment with capture panels, which include all nu-
clear genes with known human disease association (clinical 
exome panels), could overcome this limitation in the future.
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